Andrew Booth bought $384K of AbCellera Biologics (ABCL)
Executed Aug 14, disclosed Aug 14, the same day.
Over the 21 trading sessions from the disclosed entry session (Aug 14), the stock returned +3.0% (delay-adjusted); from the execution session (Aug 14), +3.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Andrew Booth (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in AbCellera Biologics Inc. (ABCL). Across 2 priced purchase filings, the average 21-session return was -0.9% from execution and -0.9% from disclosure (delay-adjusted; derived). The largest single filing was $384K of ABCL (37,200 sh × $10.32, as filed), executed Aug 14.
Healthcare · AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the Unit…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→42,600 sh × $3.42
Exec Feb 27
Filed Feb 27 · 2:48 PM ET